STRYKER Q2 FY26 earnings call SYK

Stryker continued its recovery from the Q1 cybersecurity incident, successfully ramping overall production to meet ongoing demand. Management noted that plants have been operating consistently since April 1, providing clear visibility for the second half. This production ramp is crucial for fulfilling the elevated backlog, particularly for capital equipment, and is expected to drive strong growth through the remainder of the year.

Capital delivery was a key driver of Q2 growth, with the company exiting the quarter with an elevated backlog and strong orders. Demand for capital products remains robust, and the hospital capital environment is expected to stay strong. The U.S. procedural environment is stable, with Stryker's diversified portfolio primarily supporting high-acuity, medically necessary care, which continues to see strong clinical demand, underpinned by an aging population and chronic disease trends.

The Mako robotics platform achieved its best-ever Q2 for installations both domestically and internationally, with utilization rates trending upward. The Mako RPS (Robotic-assisted Positioning System) recently moved to full commercial launch in the U.S., expanding the robotics portfolio. Additionally, new products like Triathlon Gold, its medial stabilized insert, and the Encompass total ankle replacement system (with PROPHECY planning) are rapidly moving to full commercial launch, with the Pangea trauma plating system launching in Europe in Q4.

The Peripheral Vascular business experienced a significant setback with a 6.7% decline in U.S. organic sales due to an acute supply disruption at one plant, leading to a meaningful backorder situation and lost sales. Management has addressed the issue and expects backorders to reach a manageable level by the end of Q3. Despite the hiccup, confidence remains high in the long-term outlook for the business, including the recently closed ADS acquisition, and the sales force is now stable and focused on recovery.

M&A remains Stryker's primary capital allocation priority, with a robust pipeline of opportunities. However, given strong cash flow generation and current valuation compression in the medtech sector, the company plans to resume opportunistic share repurchases in Q3 FY26. A prior Board approval provides approximately $1 billion for buybacks, with the exact amount and timing dependent on deal flow and stock valuation.

Regarding Medicare reimbursement for large joint replacement, management views initial proposed rules with 'sticker shock' as a recurring pattern, expecting them to normalize after industry feedback. The shift of orthopedic procedures to Ambulatory Surgical Centers (ASCs) continues steadily, now representing high teens percent (pushing 20%) of procedures, up from 5% pre-COVID. Stryker sees this trend as favorable, as it can win in ASCs across its portfolio and assists customers in designing these facilities.

The mechanical thrombectomy market holds significant growth potential, with a major catalyst expected from the Peerless 2 study readout in mid-2027. This high-powered clinical trial is anticipated to 'blow the market open.' While new competitors are emerging, primarily in aspiration, Stryker offers a full suite of products. The company is also excited about the ADS acquisition, with its IVL product for above-the-knee peripheral vascular potentially launching by year-end, and a coronary indication trial underway.